Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia

J. Malcikova, K. Stano-Kozubik, B. Tichy, B. Kantorova, S. Pavlova, N. Tom, L. Radova, J. Smardova, F. Pardy, M. Doubek, Y. Brychtova, M. Mraz, K. Plevova, E. Diviskova, A. Oltova, J. Mayer, S. Pospisilova, M. Trbusek,

. 2015 ; 29 (4) : 877-885.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15022976

Grant support
NT13493 MZ0 CEP Register
NT13519 MZ0 CEP Register

In chronic lymphocytic leukemia (CLL), the worst prognosis is associated with TP53 defects with the affected patients being potentially directed to alternative treatment. Therapy administration was shown to drive the selection of new TP53 mutations in CLL. Using ultra-deep next-generation sequencing (NGS), we performed a detailed analysis of TP53 mutations' clonal evolution. We retrospectively analyzed samples that were assessed as TP53-wild-type (wt) by FASAY from 20 patients with a new TP53 mutation detected in relapse and 40 patients remaining TP53-wt in relapse. Minor TP53-mutated subclones were disclosed in 18/20 patients experiencing later mutation selection, while only one minor-clone mutation was observed in those patients remaining TP53-wt (n=40). We documented that (i) minor TP53 mutations may be present before therapy and may occur in any relapse; (ii) the majority of TP53-mutated minor clones expand to dominant clone under the selective pressure of chemotherapy, while persistence of minor-clone mutations is rare; (iii) multiple minor-clone TP53 mutations are common and may simultaneously expand. In conclusion, patients with minor-clone TP53 mutations carry a high risk of mutation selection by therapy. Deep sequencing can shift TP53 mutation identification to a period before therapy administration, which might be of particular importance for clinical trials.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15022976
003      
CZ-PrNML
005      
20240516094828.0
007      
ta
008      
150709s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/leu.2014.297 $2 doi
035    __
$a (PubMed)25287991
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Malčíková, Jitka, $d 1979- $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic [2] Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 mub2011655946
245    10
$a Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia / $c J. Malcikova, K. Stano-Kozubik, B. Tichy, B. Kantorova, S. Pavlova, N. Tom, L. Radova, J. Smardova, F. Pardy, M. Doubek, Y. Brychtova, M. Mraz, K. Plevova, E. Diviskova, A. Oltova, J. Mayer, S. Pospisilova, M. Trbusek,
520    9_
$a In chronic lymphocytic leukemia (CLL), the worst prognosis is associated with TP53 defects with the affected patients being potentially directed to alternative treatment. Therapy administration was shown to drive the selection of new TP53 mutations in CLL. Using ultra-deep next-generation sequencing (NGS), we performed a detailed analysis of TP53 mutations' clonal evolution. We retrospectively analyzed samples that were assessed as TP53-wild-type (wt) by FASAY from 20 patients with a new TP53 mutation detected in relapse and 40 patients remaining TP53-wt in relapse. Minor TP53-mutated subclones were disclosed in 18/20 patients experiencing later mutation selection, while only one minor-clone mutation was observed in those patients remaining TP53-wt (n=40). We documented that (i) minor TP53 mutations may be present before therapy and may occur in any relapse; (ii) the majority of TP53-mutated minor clones expand to dominant clone under the selective pressure of chemotherapy, while persistence of minor-clone mutations is rare; (iii) multiple minor-clone TP53 mutations are common and may simultaneously expand. In conclusion, patients with minor-clone TP53 mutations carry a high risk of mutation selection by therapy. Deep sequencing can shift TP53 mutation identification to a period before therapy administration, which might be of particular importance for clinical trials.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protinádorové látky $x aplikace a dávkování $x škodlivé účinky $7 D000970
650    _2
$a B-lymfocyty $x účinky léků $x metabolismus $x patologie $7 D001402
650    _2
$a klonální evoluce $x účinky léků $x genetika $7 D060965
650    _2
$a buněčné klony $7 D002999
650    _2
$a ženské pohlaví $7 D005260
650    12
$a regulace genové exprese u leukemie $7 D015973
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x farmakoterapie $x genetika $x mortalita $x patologie $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a recidiva $7 D012008
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a signální transdukce $7 D015398
650    _2
$a analýza přežití $7 D016019
650    _2
$a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Staňo Kozubík, Kateřina $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $7 xx0141563
700    1_
$a Tichý, Boris $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic [2] Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0312236
700    1_
$a Kantorová, Barbara $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $7 _AN052877
700    1_
$a Pavlová, Šárka $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic [2] Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0117816
700    1_
$a Tom, Nikola $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic [2] Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0230111
700    1_
$a Radova, L $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Šmardová, Jana, $d 1961- $u Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 mzk2005304278
700    1_
$a Pardy, Filip $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $7 xx0230134
700    1_
$a Doubek, Michael, $d 1972- $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic [2] Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 mzk2004217554
700    1_
$a Brychtová, Yvona $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0105542
700    1_
$a Mráz, Marek $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic [2] Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0122131
700    1_
$a Plevová, Karla $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic [2] Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0158852
700    1_
$a Divíšková, Eva $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0317345
700    1_
$a Oltová, Alexandra $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0110415
700    1_
$a Mayer, Jiří, $d 1960- $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic [2] Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 nlk20000083651
700    1_
$a Pospíšilová, Šárka, $d 1969- $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic [2] Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0101843
700    1_
$a Trbušek, Martin, $d 1969- $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic [2] Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0101488
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 29, č. 4 (2015), s. 877-885
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25287991 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20240516094823 $b ABA008
999    __
$a ok $b bmc $g 1083315 $s 905969
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 29 $c 4 $d 877-885 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
GRA    __
$a NT13493 $p MZ0
GRA    __
$a NT13519 $p MZ0
LZP    __
$a Pubmed-20150709

Find record

Citation metrics

Archiving options